The CompassHER2 Trials Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer

CIRB #H-40381/ CTSU #EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients who Achieve a Pathologic Complete Response

CIRB #H-42687/ CTSU #A011801 (CompassHER2-RD): CompassHER2 Residual Disease РA Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared With T-DM1 and Tucatinib 

CIRB #H-43958/ ETCTN 10525: A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel in Patients With Metastatic Triple-Negative Breast Cancer (pending CIRB approval)

CIRB #H-42956/ ETCTN #10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (temporary closure)

IRB #H-33188/ BMC #DOSI: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI)

IRB #H-37386/ CTSU #EA1151 (TMIST): Tomosynthesis Mammographic Imaging Screening Trial